These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 23490222

  • 1. Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection.
    Pina JM, Clotet L, Ferrer A, Sala MR, Garrido P, Salleras L, Domínguez A.
    Respir Med; 2013 May; 107(5):768-77. PubMed ID: 23490222
    [Abstract] [Full Text] [Related]

  • 2. Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials.
    Esfahani K, Aspler A, Menzies D, Schwartzman K.
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1340-6. PubMed ID: 22283892
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection.
    Pina JM, Clotet L, Ferrer A, Sala MR, Garrido P, Salleras L, Domínguez A.
    Eur J Clin Microbiol Infect Dis; 2013 May; 32(5):647-55. PubMed ID: 23238684
    [Abstract] [Full Text] [Related]

  • 4. Latent tuberculosis infection in children: a call for revised treatment guidelines.
    Finnell SM, Christenson JC, Downs SM.
    Pediatrics; 2009 Mar; 123(3):816-22. PubMed ID: 19255008
    [Abstract] [Full Text] [Related]

  • 5. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
    Huang YW, Yang SF, Yeh YP, Tsao TC, Tsao SM.
    Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of latent tuberculosis infection: An update.
    Lobue P, Menzies D.
    Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026
    [Abstract] [Full Text] [Related]

  • 11. Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis.
    Jasmer RM, Snyder DC, Chin DP, Hopewell PC, Cuthbert SS, Antonio Paz E, Daley CL.
    Am J Respir Crit Care Med; 2000 Nov; 162(5):1648-52. PubMed ID: 11069790
    [Abstract] [Full Text] [Related]

  • 12. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
    Jasmer RM, Snyder DC, Saukkonen JJ, Hopewell PC, Bernardo J, King MD, Kawamura LM, Daley CL, Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection Study Investigators.
    Clin Infect Dis; 2004 Feb 01; 38(3):363-9. PubMed ID: 14727206
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of treating latent tuberculous infection: a step towards elimination?
    Diel R, Loddenkemper R, Sotgiu G, Migliori GB.
    Int J Tuberc Lung Dis; 2013 Dec 01; 17(12):1515. PubMed ID: 24200259
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity.
    Ziakas PD, Mylonakis E.
    Clin Infect Dis; 2009 Dec 15; 49(12):1883-9. PubMed ID: 19911936
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis.
    Rose DN.
    Ann Intern Med; 1998 Nov 15; 129(10):779-86. PubMed ID: 9841583
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.